10 January 2024
Ropes & Gray Advises AbbVie in Strategic Collaborations with Umoja Biopharma to Develop Novel In-Situ CAR-T Cell Therapies
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Abigail Gregor Lead | Ropes & Gray | Partner | life sciences licensing | Not stated |
| Evan Tallmadge | Ropes & Gray | Associate | life sciences licensing | Not stated |
| Kevin Tang | Ropes & Gray | Associate | life sciences licensing | Not stated |
| Jenny Zhang | Ropes & Gray | Associate | life sciences licensing | Not stated |
| Brad Flint | Ropes & Gray | Partner | emerging companies and venture capital | Not stated |
| Joe Muller | Ropes & Gray | Associate | emerging companies and venture capital | Not stated |
Stated terms
- Stated value
- USD 1.44bn ($1.44 billion)
- What the figure measures
- Not stated
- Client
- AbbVieBuy-side
- Counterparties
- Umoja Biopharma (Sell-side)